Jacob Fredsoe

List of Publications by Year
in descending order

20 papers	527 citations	623734 14 h-index	752698 20 g-index
20 all docs	20 docs citations	20 times ranked	789 citing authors

#	Article	IF	Citations
1	Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine. European Urology Focus, 2018, 4, 825-833.	3.1	86
2	^{68}Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer. Journal of Nuclear Medicine, 2021, 62, 214-220.	5.0	64
3	DNA Hairpins as Temperature Switches, Thermometers and Ionic Detectors. Sensors, 2013, 13, 5937-5944.	3.8	45
4	DNA Topoisomerases Maintain Promoters in a State Competent for Transcriptional Activation in Saccharomyces cerevisiae. PLoS Genetics, 2012, 8, e1003128.	3.5	40
5	A five-microRNA model (pCaP) for predicting prostate cancer aggressiveness using cell-free urine. International Journal of Cancer, 2019, 145, 2558-2567.	5.1	36
6	Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors. Journal of Pathology, 2021, 255, 155-165.	4.5	36
7	Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients. Annals of Oncology, 2018, 29, 2003-2009.	1.2	29
8	Aberrant DOCK2, GRASP, HIF3A and PKFP Hypermethylation has Potential as a Prognostic Biomarker for Prostate Cancer. International Journal of Molecular Sciences, 2019, 20, 1173.	4.1	28
9	Profiling of Circulating microRNAs in Prostate Cancer Reveals Diagnostic Biomarker Potential. Diagnostics, 2020, 10, 188.	2.6	22
10	Independent Validation of a Diagnostic Noninvasive 3-MicroRNA Ratio Model (uCaP) for Prostate Cancer in Cell-Free Urine. Clinical Chemistry, 2019, 65, 540-548.	3.2	20
11	Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential. Cells, 2020, 9, 1362.	4.1	20
12	The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer. Genome Medicine, 2022, 14, 8.	8.2	19
13	High-Throughput and Automated Acoustic Trapping of Extracellular Vesicles to Identify microRNAs With Diagnostic Potential for Prostate Cancer. Frontiers in Oncology, 2021, 11, 631021.	2.8	17
14	Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells. American Journal of Pathology, 2019, 189, 2377-2388.	3.8	16
15	Top2 and Sgs1-Top3 Act Redundantly to Ensure rDNA Replication Termination. PLoS Genetics, 2015, 11, e1005697.	3.5	15
16	Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling. Genome Medicine, 2022, 14, 9.	8.2	14
17	DNA Topoisomerases Are Required for Preinitiation Complex Assembly during GAL Gene Activation. PLoS ONE, 2015, 10, e0132739.	2.5	11
18	The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial. PLoS Medicine, 2020, 17, e1003033.	8.4	6

#	Article	IF	Citations
19	Independent validation of a pre-specified four-kallikrein marker model for prediction of adverse pathology and biochemical recurrence. British Journal of Cancer, 2022, 126, 1004-1009.	6.4	2
20	A genetic risk assessment for prostate cancer influences patients' risk perception and use of repeat PSA testing: a cross-sectional study in Danish general practice. BJGP Open, 2020, 4, bjgpopen20X101039.	1.8	1